What is the address of GESTIPHARMA?

The registered office of GESTIPHARMA is located at Rue de Montreuil sous Bois(H.) 15, 7022 Mons.

Is GESTIPHARMA still active?

Yes. According to the CBE (29 October 2026) GESTIPHARMA is active, legal situation “Normale toestand”, started on 31 December 1983.

Is GESTIPHARMA registered on Peppol?

Yes, GESTIPHARMA is registered on the Peppol network with ID 0208:0425530684.

What is the enterprise number of GESTIPHARMA?

The enterprise number of GESTIPHARMA is BE0425530684.

When was GESTIPHARMA founded?

GESTIPHARMA was founded on 31 December 1983.

Who are the directors of GESTIPHARMA?

According to the 2025 annual accounts, the directors of GESTIPHARMA are: FINPHARMA SA, Pierre-Pascal HECQ.

Is GESTIPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 December 1983; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did GESTIPHARMA make in 2025?

GESTIPHARMA posted a profit after taxes of € 77,529 in financial year 2025.

What is the revenue of GESTIPHARMA?

As a small company, GESTIPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 230,159.

GESTIPHARMA (Public Limited) - Mons - BE0425530684

Q: What does GESTIPHARMA do?

GESTIPHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Public Limited, started on 31 December 1983, 1 establishment.

Dossier GESTIPHARMA, printed on 29 October 2026 from databakkes.be/en/0425530684/gestipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

GESTIPHARMA from Mons, company number BE0425530684, closed financial year 2025 with a result of € 77,529 after tax. For that financial year GESTIPHARMA recorded a gross margin of € 230,159 and equity of € 815,663. Compared with financial year 2024, the result moved from € -40,570 to € 77,529. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 815,663

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 77,529

▲ still € 40,570 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 409,067

▲ 68% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -668,315.

People and assets in 2025

Wage cost

€ 69,041

▼ 21% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6,045

▲ 58% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 14

▼ 98% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 43,744

▲ 50% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 49,567 Gross margin 2022: € 49,567 First fiscal year in the series	€ 151,445 Gross margin 2023: € 151,445 ▲ 206% vs 2022 (€ 49,567) Favourable step	€ 144,990 Gross margin 2024: € 144,990 ▼ 4% vs 2023 (€ 151,445) Unfavourable step	€ 230,159 Gross margin 2025: € 230,159 ▲ 59% vs 2024 (€ 144,990) Favourable step	▲ 59%
Profit after taxes	€ -93,942 Profit after taxes 2022: € -93,942 First fiscal year in the series	€ 1,416 Profit after taxes 2023: € 1,416 ▲ € 95,358 vs 2022 (€ -93,942) Favourable step	€ -40,570 Profit after taxes 2024: € -40,570 ▼ € 41,986 vs 2023 (€ 1,416) Unfavourable step	€ 77,529 Profit after taxes 2025: € 77,529 ▲ € 118,099 vs 2024 (€ -40,570) Favourable step	▲ € 118,099
Equity	€ 777,288 Equity 2022: € 777,288 First fiscal year in the series	€ 778,704 Equity 2023: € 778,704 Unchanged (€ 777,288) Favourable step	€ 738,134 Equity 2024: € 738,134 ▼ 5% vs 2023 (€ 778,704) Unfavourable step	€ 815,663 Equity 2025: € 815,663 ▲ 11% vs 2024 (€ 738,134) Favourable step	▲ 11%
Total debts	€ 9,556 Total debts 2022: € 9,556 First fiscal year in the series	€ 31,993 Total debts 2023: € 31,993 ▲ 235% vs 2022 (€ 9,556) Unfavourable step	€ 29,851 Total debts 2024: € 29,851 ▼ 7% vs 2023 (€ 31,993) Favourable step	€ 43,758 Total debts 2025: € 43,758 ▲ 47% vs 2024 (€ 29,851) Unfavourable step	▲ 47%
Cash	€ 100,196 Cash 2022: € 100,196 First fiscal year in the series	€ 151,480 Cash 2023: € 151,480 ▲ 51% vs 2022 (€ 100,196) Favourable step	€ 244,073 Cash 2024: € 244,073 ▲ 61% vs 2023 (€ 151,480) Favourable step	€ 409,067 Cash 2025: € 409,067 ▲ 68% vs 2024 (€ 244,073) Favourable step	▲ 68%
Land & buildings	€ 685,298 Land & buildings 2022: € 685,298 First fiscal year in the series	€ 607,997 Land & buildings 2023: € 607,997 ▼ 11% vs 2022 (€ 685,298) Unchanged	€ 516,020 Land & buildings 2024: € 516,020 ▼ 15% vs 2023 (€ 607,997) Unchanged	€ 441,690 Land & buildings 2025: € 441,690 ▼ 14% vs 2024 (€ 516,020) Unchanged	▼ 14%
Retained profit	€ -706,690 Retained profit 2022: € -706,690 First fiscal year in the series	€ -705,274 Retained profit 2023: € -705,274 Unchanged (€ -706,690) Favourable step	€ -745,844 Retained profit 2024: € -745,844 ▼ € 40,570 vs 2023 (€ -705,274) Unfavourable step	€ -668,315 Retained profit 2025: € -668,315 ▲ € 77,529 vs 2024 (€ -745,844) Favourable step	▲ € 77,529
Balance sheet total	€ 786,844 Balance sheet total 2022: € 786,844 First fiscal year in the series	€ 810,697 Balance sheet total 2023: € 810,697 ▲ 3% vs 2022 (€ 786,844) Unchanged	€ 767,985 Balance sheet total 2024: € 767,985 ▼ 5% vs 2023 (€ 810,697) Unchanged	€ 859,421 Balance sheet total 2025: € 859,421 ▲ 12% vs 2024 (€ 767,985) Unchanged	▲ 12%

Key figures of GESTIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to GESTIPHARMA?

What happened at GESTIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 FINPHARMA SA stepped down as director. NBB
2028 Pierre-Pascal HECQ stepped down as director. NBB
Jun 30, 2026 New annual accounts for financial year 2025: profit of € 77,529. Source: NBB ↗
2022 FINPHARMA SA became a director. NBB
2022 Pierre-Pascal HECQ became a director. NBB
Jan 1, 1984 New establishment in Frameries. KBO
Dec 31, 1983 Start of the company according to the CBE. KBO

In short

From € 93,942 loss in 2022 to € 77,529 profit in 2025.

Paid € 488 in corporate taxes since 2022.

Best year ever: 2025, with € 77,529 profit.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

FINPHARMA SA

Director · represented by PHILIPPE BOULANGER

Also active at: Les Pharmacies Réunies, P.J. VLEUGELS et Cie, PHARMANET, FINANCIERE DU LOUVY, GERPINNES PHARMA

since 2022 · until 2028

Pierre-Pascal HECQ

Managing director

Also active at: Les Pharmacies Réunies, Immobilière Général Léman, P.J. VLEUGELS et Cie, PHARMACIE CLAERHOUT, IMMOBILIERE SAINT GEORGES, PHARMACIE SCHNEIDER - DEPOUHON, ASSCOT, BEPHAR +5 more

since 2022 · until 2028

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Montreuil sous Bois(H.) 15

7022 Mons

2.024.258.653

Rue Montavaux 155

7080 Frameries

Active since 1 January 1984

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0425.530.684

VAT number

BE 0425.530.684

Registered office

Rue de Montreuil sous Bois(H.) 15, 7022 Mons

Names & denominations

GESTIPHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

31 December 1983

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗